Harvard bioscience inc (HBIO)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash flows from operating activities:
Net Loss

-4,687

-2,922

-865

-4,307

-19,039

2,355

-1,830

2,370

3,812

19,015

7,233

Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation

1,987

2,423

1,317

1,532

1,745

1,253

1,298

1,270

1,276

1,196

1,204

Amortization of intangible assets

5,746

5,431

2,442

-

-

-

-

-

-

-

-

Amortization of intangible assets

-

-

-

2,722

2,819

2,578

2,590

2,752

2,746

2,364

1,844

Amortization of deferred financing costs

385

645

44

91

86

61

46

52

89

89

56

Stock-based compensation expense

3,034

3,044

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

-

-

3,500

3,497

2,755

2,156

2,670

3,321

2,863

2,756

2,514

Impairment charges

1,460

-

-

676

0

0

-

-

-

-

-

Gain on sale of Denville

-

1,251

0

1,190

0

0

-

-

-

-

-

Provision for allowance for doubtful accounts

288

25

-109

309

-7

-67

172

-31

67

-150

-7

Deferred income taxes

398

2,861

-

-

-

-

-

-

-

-

-

Other non-cash charges

-188

-25

-

-

-

-

-

-

-

-

-

Receivable for the earn-out related to discontinued assets

-

-

-

-

-

-

440

1,344

0

0

-

Gain on acquisition contingencies

-

-

-

-

-

-

-

-

-

429

2,600

(Gain) loss on sales of fixed assets

-

-

12

0

-25

810

0

24

19

15

-12

Gain loss on disposal of business

-

-

-93

-

-

-

-

-

-

-

-

Non cash restructuring charge

-

-

-

-27

-85

-120

-46

-13

210

79

230

Amortization Of Catalog Costs

-

-

42

20

9

47

101

184

307

357

348

Deferrred Income Taxes

-

-

-1,584

-279

15,116

1,412

-2,441

-731

-849

-11,732

469

Changes in operating assets and liabilities:
Accounts receivable

-468

2,792

-196

-566

1,340

735

-436

-1,154

-232

1,088

-3,233

Inventories

-3,260

-2,554

548

-1,248

1,223

3,056

-1,921

-1,174

1,705

1,238

41

Other current assets

-165

124

-

-

-

-

-

-

-

-

-

Accounts payable

-2,048

1,593

-

-

-

-

-

-

-

-

-

Increase in other receivables and other assets

-

-

102

658

-755

370

1,020

925

73

-123

-1,102

Increase (decrease) in accounts payable

-

-

-918

-2,413

2,577

1,069

-41

-905

69

56

-1,024

Accrued income taxes

-363

612

212

-195

-311

-269

323

213

-544

443

-338

Other current liabilities

-1,256

-3,149

-

-

-

-

-

-

-

-

-

Deferred revenue

121

2,492

-

-

-

-

-

-

-

-

-

(Decrease) increase in accrued expenses

-

-

-736

871

-1,511

-345

847

-485

-1,368

386

213

(Decrease) increase in deferred revenue

-

-

95

-187

120

28

146

-48

31

23

-162

Increase (decrease) in other liabilities

-

-

-2,010

727

-1,786

-836

-672

78

-496

58

2,223

Other long-term liabilities

-305

-2,861

-

-

-

-

-

-

-

-

-

Net cash provided by operating activities

8,045

2,884

1,057

5,383

705

4,351

4,060

8,062

6,648

12,293

16,509

Cash flows from investing activities:
Additions to property, plant and equipment

1,216

986

890

-

-

-

-

-

-

-

-

Other

15

16

-

-

-

-

-

-

-

-

-

Additions to property, plant and equipment

-

-

-

-1,445

-2,960

-2,005

-1,622

-1,769

-1,506

-844

-1,376

Additions to catalog costs

-

-

-39

-34

-18

0

-57

-62

-252

-418

-164

Proceeds from sales of property, plant and equipment

-

-

12

0

6

1,141

66

33

25

31

4

Proceeds from sale of discontinued operations

-

-

-

-

-

-

1,784

0

0

-

-

Acquisition, net of cash acquired

-

68,548

0

0

4,545

12,653

0

2,878

5,465

7,115

20,764

Disposition, net of cash sold

1,002

15,754

0

1,417

0

0

-

-

-

-

-

Net cash used in investing activities

-229

-53,796

-917

-62

-7,517

-13,517

171

-4,676

-7,198

-8,346

-22,300

Cash flows from financing activities:
Repayments of short-term debt

-

-

-

-

-

-

-

-

-

-

1,308

Proceeds from issuance of debt

4,300

70,700

2,750

4,000

5,800

2,200

14,550

500

0

10,350

16,900

Repayments of debt

11,703

20,198

4,702

9,050

8,350

5,500

2,750

3,850

1,708

5,663

3,674

Treasury Stock, Value Acquired, Cost Method

-

-

-

-

-

-

-

-

0

5,000

2,404

Transfer of cash and cash equivalents to HART

-

-

0

-

-

-

15,041

0

0

-

-

Payments of debt issuance costs

-

2,006

0

0

32

0

312

0

0

-

-

Taxes paid for issuance of stock

-221

4,557

-

-

-

-

-

-

-

-

-

Net proceeds from issuance of common stock

-

-

160

182

2,042

2,066

3,621

2,287

567

282

271

Net cash used in financing activities

-7,624

53,053

-1,792

-4,868

-540

-1,234

68

-1,063

-1,141

-31

9,785

Effect of exchange rate changes on cash

-30

299

-

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash

-

-

1,789

-1,601

-38

-1,237

791

442

-97

-800

-1,104

Decrease in cash and cash equivalents

162

2,440

-

-

-

-

-

-

-

-

-

Increase in cash and cash equivalents

-

-

137

-1,148

-7,390

-11,637

5,090

2,765

-1,788

3,116

2,890

Supplemental disclosures of cash flow information:
Cash paid for interest

5,496

4,987

686

-

-

-

-

-

-

-

-

Cash paid for income taxes

374

98

13

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

620

854

997

892

577

638

652

114

Cash paid for income taxes, net of refunds

-

-

-

928

963

843

1,479

1,519

2,234

1,778

1,668